SCHEMBL7126926

SCHEMBL7126926

CC(=O)Nc1nnc(Sc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.39
TDP1 Q9NUW8 4/20 0.39
ALDH1A1 P00352 5/20 0.39
POLB P06746 2/20 0.39
LMNA P02545 2/20 0.39
NPC1 O15118 6/20 0.38
RAB9A P51151 6/20 0.38
MEN1 O00255 4/20 0.38
APOBEC3A P31941 2/20 0.38
APOBEC3G Q9HC16 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
MAPT P10636 2/20 0.36
TP53 P04637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
CASP3 P42574 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7123272 0.87 HDAC6 (0.38) MAPTTP53HDAC6
SCHEMBL7115039 0.86 HDAC6 (0.38) KMT2AALDH1A1LMNANPC1RAB9A
SCHEMBL7120666 0.85 ITK (0.42)
SCHEMBL7121893 0.84 HDAC6 (0.38) KMT2ANPC1RAB9AMEN1HDAC6
SCHEMBL7114408 0.84 HDAC6 (0.37) ALDH1A1LMNANPC1RAB9AHDAC6
SCHEMBL7121247 0.84 SLC6A2 (0.37) KMT2ANPC1RAB9AMEN1HDAC6
SCHEMBL7117025 0.83 CHRNA7 (0.33) ALDH1A1LMNA
SCHEMBL7122440 0.83 HDAC6 (0.37) ALDH1A1LMNANPC1RAB9AHDAC6
SCHEMBL7120734 0.83 GAA (0.35) ALDH1A1LMNAGAA
SCHEMBL7127585 0.82 HDAC6 (0.36) KMT2ATDP1ALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 KMT2A 1264/4885TDP1 2026/4885ALDH1A1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.